Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Healthcare Facilities company Narayana Hrudayalaya announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Consolidated total operating revenue was Rs 14,754 million for Q4 FY25 as compared to Rs 12,462 million in the corresponding period of the previous year, reflecting a change of +18.4 % YoY and +10.6% QoQ. Consolidated EBITDA stood at Rs 3,846 million, reflecting a margin of 26.1% as against Rs 3,148 million in Q4FY24, translating into a change of +22.2% YoY and +18.1% QoQ. Consolidated PAT stood at Rs 1,962 million, reflecting a margin of 13.3% as compared to Rs 1,880 million in Q4FY24, translating into a change of +4.4% YoY and +1.3% QoQ. India operating revenue was Rs 11,088 million for Q4 FY25 as compared to Rs 10,020 million in the corresponding period of the previous year, reflecting a change of +10.7% YoY and +5.1% QoQ. Cayman operating revenue was Rs 3,797 million for Q4 FY25 as compared to Rs 2,528 million in the corresponding period of the previous year, reflecting a change of +50.2% YoY and +29.4% QoQ. FY25 Financial Highlights: Consolidated total operating revenue was Rs 54,830 million for FY25 as compared to Rs 48,902 million in FY24, reflecting a change of +12.1%. Consolidated EBITDA stood at Rs 13,684 million for FY25, reflecting a margin of 25.0% as against Rs 12,224 million in FY24, translating a change of +11.9%. Consolidated PAT stood at Rs 7,898 million for FY25, reflecting a margin of 14.4% as compared to Rs 7,860 million in FY24. India operating revenue was Rs 43,499 million for FY25 as compared to Rs 39,085 million in FY24, reflecting a change of +11.3%. Cayman operating revenue was Rs 11,829 million for FY25 as compared to Rs 10,261 million in FY24, reflecting a change of +15.3%. Commenting on the performance, Emmanuel Rupert, Managing Director and Group CEO, Narayana Hrudayalaya, said “The current financial year demonstrated strong performance across our units both domestic and international; we are pleased to report the highest-ever revenues and profitability margins on both quarterly as well as annual basis at the consolidated level. The performance improvement in India units has been driven by domestic volume pickup, increased realizations, and optimization in payor categories. While our flagships continue to contribute significantly, our Southern Peripheral and North units have shown significant growth this year, and we hope to build on the momentum going forward. HCCI continues to contribute significantly, delivering record revenues on both quarterly and annual basis. The new hospital in Camana Bay is fully functional and is contributing meaningfully to the overall Cayman business. We are excited with the traction in the new hospital and are confident that the region will deliver strong growth going forward. The Integrated Care business is picking up well, with our new clinics garnering sizeable footfalls. We will continue to invest in this business and are optimistic that it will be a significant driver of growth to the overall NH ecosystem. We thank the investor community for their faith in us and remain confident of delivering on expectations for the upcoming year.” Result PDF